Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.31 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18173087 | 1.00 | KDM1A (0.50) | KDM1AMAPK1SMN1; SMN2TDP1CYP1A2 | |
| SCHEMBL18173001 | 0.79 | KDM1A (0.62) | KDM1AMAPK1SMN1; SMN2TDP1CES2 | |
| SCHEMBL18172996 | 0.79 | KDM1A (0.62) | KDM1AMAPK1SMN1; SMN2TDP1CES2 | |
| SCHEMBL18173167 | 0.75 | KDM1A (0.45) | KDM1ASMN1; SMN2TDP1CYP1A2CYP2C9 | |
| SCHEMBL18173154 | 0.71 | KDM1A (0.51) | KDM1AMAPK1 | |
| SCHEMBL18173156 | 0.71 | KDM1A (0.51) | KDM1AMAPK1 | |
| SCHEMBL18182649 | 0.71 | KDM1A (0.51) | KDM1ASMN1; SMN2 | |
| SCHEMBL18173086 | 0.68 | NFE2L2 (0.38) | SMN1; SMN2CYP1A2 | |
| SCHEMBL18173088 | 0.68 | NFE2L2 (0.38) | SMN1; SMN2CYP1A2 | |
| SCHEMBL18173412 | 0.68 | KDM1A (1.00) | KDM1ACYP1A2CYP2C9CYP2C19CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| EP-3286172-B1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. | 2018-10-11 | — | — | US | disclosed |
| EP-3286172-A1 | LSD1 INHIBITORS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172496-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016172496-A1 | LSD1 INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180290976-A1 | LSD1 INHIBITORS AND USES THEREOF | KDM1B, KDM1A, KDM2A | KDM1A 2/4885MAPK1 1481/4885SMN1; SMN2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.